Roivant Sciences LTD 10-K annual reports

Roivant Sciences Ltd. filed its annual report detailing pipeline progress, financial performance, and strategic outlook, highlighting significant R&D investments and a strong cash position.

Roivant Sciences Ltd. reported a net loss of $356.7 million for fiscal year 2025, primarily due to increased operating expenses and the absence of a large one-time gain from the prior year's Telavant divestiture, despite significant clinical progress across its diverse biopharmaceutical pipeline.

Roivant Sciences Ltd. released its fiscal year 2024 results, showcasing significant revenue growth and strategic advancements, including the sale of Telavant to Roche for $7.1 billion.